Over 120 million people suffer from allergies in the US, making allergies the most prevalent chronic illness in the country. Founded in 2021 by CEO Ken Chahine, Obvious Ventures and Juxtapose, Nectar’s mission is to put an end to allergies, and in turn, build healthier, more productive communities. Nectar is building the first vertically-integrated platform for allergies, including a compounding pharmacy, lab testing facility, allergist physician network, and digital devices to align incentives and deliver an exceptional customer experience. Nectar’s world-class medical board advises on every aspect of Nectar’s comprehensive allergy treatment program and helps drive clinical research efforts, ensuring all products and services meet the highest safety and efficacy standards. Nectar will soon be opening clinics, known as Nectar Allergy Centers, in major metro areas across the country as part of its comprehensive care vision. Nectar clinics build upon the company’s virtual care offering by enabling the company to expand to more complex allergic conditions, including asthma, food allergies, and atopic dermatitis.
Dr. Ken Chahine partnered with Juxtapose and Obvious Ventures to found Nectar after an impressive career at AncestryDNA, which he founded and led to over $500mm in direct sales. Prior to that, he served as CEO of gene therapy business Avigen. Early in his career, Ken practiced patent law on behalf of bioscience companies.